Anecortave Acetate
drugOn this page
Also known as AL 3789AL 4940AL-3789AL-4940AL3789AL4940AnecortavaAnecortaveAnecortave (usan)Anecortave desacetateNSC-15475NSC-24345SID144206221
Summary
Anecortave Acetate (CHEMBL2106613) is a phase-3 clinical-stage small molecule (ATC S01LA02); indicated across 9 conditions including ocular vascular disorder and age-related macular degeneration.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: S01LA02
- Indications: 9 conditions
- Clinical trials: 29
- Chemistry: 386.5 Da · C23H30O5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2106613 |
| Name | Anecortave Acetate |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 111332 |
| ATC | S01LA02 |
| Molecular formula | C23H30O5 |
| Molecular weight | 386.5 |
| InChIKey | YUWPMEXLKGOSBF-GACAOOTBSA-N |
SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC=C3[C@H]2CCC4=CC(=O)CC[C@@]43C)C)O
IUPAC name: [2-[(8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
Also known as: AL 3789, AL 4940, AL-3789, AL-4940, AL3789, AL4940, Anecortava, Anecortave, Anecortave (usan), Anecortave acetate, Anecortave desacetate, NSC-15475
Patent coverage: 1,768 distinct patent families (7,761 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Glucocorticoid receptor.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| NR3C1 | 5.77 | AC50 | 1700 | nM | CHEMBL_ACT_25176117 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| ocular vascular disorder | 3 | MONDO:0005552 | EFO:0005753 |
| age-related macular degeneration | 3 | MONDO:0005150 | EFO:0001365 |
| macular degeneration | 3 | MONDO:0003004 | EFO:0009606 |
| open-angle glaucoma | 2 | MONDO:0005338 | EFO:0004190 |
| eye disorder | 2 | MONDO:0005328 | EFO:0003966 |
| retinal vein occlusion | 2 | MONDO:0006951 | EFO:1001157 |
| telangiectasis | 2 | MONDO:0001576 | MONDO:0001576 |
| Coats disease | 2 | MONDO:0010269 | MONDO:0010269 |
| diabetic retinopathy | 1 | MONDO:0005266 | EFO:0003770 |
Clinical trials
Total trials: 29.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 14 |
| PHASE3 | 7 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 2 |
| Not specified | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00051129 | PHASE3 | COMPLETED | Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD) |
| NCT00058994 | PHASE3 | COMPLETED | An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD |
| NCT00065728 | PHASE3 | TERMINATED | Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD |
| NCT00299507 | PHASE3 | COMPLETED | Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD) |
| NCT00307398 | PHASE3 | TERMINATED | Anecortave Acetate Risk-Reduction Trial (AART) |
| NCT00332657 | PHASE3 | TERMINATED | Anecortave Acetate Risk Reduction Trial (AART) |
| NCT00333216 | PHASE3 | TERMINATED | Anecortave Acetate Risk-Reduction Trial (AART) |
| NCT00691717 | PHASE2/PHASE3 | COMPLETED | Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension |
| NCT00705770 | PHASE2/PHASE3 | WITHDRAWN | A Multi-Dose Study With a Treatment for Open-Angle Glaucoma |
| NCT00211315 | PHASE2 | COMPLETED | Treatment of Congenital Telangiectasia (Coat’s Disease) With Open-label Anecortave Acetate (15mg.) |
| NCT00211328 | PHASE2 | COMPLETED | Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.). |
| NCT00211354 | PHASE2 | WITHDRAWN | Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.) |
| NCT00211367 | PHASE2 | TERMINATED | Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg) |
| NCT00211432 | PHASE2 | COMPLETED | Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg) |
| NCT00211458 | PHASE2 | COMPLETED | Treatment of Age-Related Macular Degeneration With Anecortave Acetate |
| NCT00211471 | PHASE2 | TERMINATED | Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). |
| NCT00211484 | PHASE2 | COMPLETED | Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care. |
| NCT00315640 | PHASE2 | COMPLETED | Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation |
| NCT00320203 | PHASE2 | COMPLETED | Anecortave Acetate in Patients With Open-angle Glaucoma |
| NCT00346866 | PHASE2 | COMPLETED | Anecortave Acetate Versus Placebo in AMD Patients Following PDT |
| NCT00346957 | PHASE2 | COMPLETED | A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration |
| NCT00451152 | PHASE2 | COMPLETED | Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma |
| NCT00489840 | PHASE1/PHASE2 | COMPLETED | Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate |
| NCT00788541 | PHASE2 | TERMINATED | A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension |
| NCT00211406 | PHASE1 | TERMINATED | Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg) |
| NCT00211419 | PHASE1 | COMPLETED | Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD) |
| NCT00570479 | PHASE1 | COMPLETED | Prophylactic Anecortave Acetate in Patients With a Retisert Implant |
| NCT00349739 | Not specified | NO_LONGER_AVAILABLE | Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate |
| NCT00884039 | Not specified | TERMINATED | Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).